OncoMatch/Clinical Trials/NCT06617416
A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC
Is NCT06617416 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Cadonilimab (AK104) and Sugemalimab for nsclc (non-small cell lung cancer).
Treatment: Cadonilimab (AK104) · Sugemalimab — This study compares the efficacy and safety of AK104 versus Sugemalimab as consolidation therapy in patients with unresectable, locally advanced NSCLC who have not progressed following concurrent or sequential chemoradiotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: EGFR wild-type
Required: ROS1 wild-type
Disease stage
Required: Stage III
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: chemoradiotherapy — concurrent or sequential
Concurrent or sequential chemoradiotherapy completed 1 to 42 days prior to the first dose. No disease progression after concurrent or sequential chemoradiotherapy.
Cannot have received: immunotherapy
Previously received immunotherapy
Cannot have received: biotherapy
Previously received biotherapy
Cannot have received: anti-angiogenic drugs
Previously received anti-angiogenic drugs
Cannot have received: small molecule targeted drugs
Previously received small molecule targeted drugs
Cannot have received: consolidation chemotherapy
Consolidation chemotherapy is not allowed after radiotherapy
Lab requirements
Blood counts
adequate organ and bone marrow function
Kidney function
adequate organ and bone marrow function
Liver function
adequate organ and bone marrow function
Adequate organ and bone marrow function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06617416 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immunotherapy, biotherapy, anti-angiogenic drugs disqualifies patients from enrollment.
Does this trial require ALK?
Yes, ALK wild-type is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR wild-type is a required biomarker for enrollment.
Does this trial require ROS1?
Yes, ROS1 wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage III is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages